Document is current

Article History

Accepted: 10 March 2022

First Online: 4 November 2022

Declarations

:

: J.M. Hebel is a member of the guideline group “Management of first epileptic seizure and epilepsies” (“Management erster epileptischer Anfall und Epilepsien”) of the German Neurological Society. M. Holtkamp has received consulting and lecture fees from Angelini/Arvelle, Bial, Desitin, Eisai, GW Pharma, UCB, and Zogenix in the period 2018–2022. These are unrelated to the content of this article. He is also coordinator of the guideline group “Management of first epileptic seizure and epilepsies” of the German Neurological Society.

: For this article no studies with human participants or animals were performed by any of the authors. All studies mentioned were in accordance with the ethical standards indicated in each case.

: The supplement containing this article is not sponsored by industry.

Free to read: This content has been made available to all.